Lou Gehrig's Disease News and Research RSS Feed - Lou Gehrig's Disease News and Research

Lou Gehrig's Disease or Amyotrophic Lateral Sclerosis (ALS) is a neurological disorder characterized by progressive degeneration of motor neuron cells in the spinal cord and brain, which ultimately results in paralysis and death. The disease takes its less-scientific name from Lou Gehrig, a baseball player with the New York Yankees in the late 1920s and 1930s, who was forced to retire in 1939 as a result of the loss of motor control caused by the disease.

In 1991, a team of researchers linked familial ALS to chromosome 21. Two years later, the SOD1 gene was identified as being associated with many cases of familial ALS. The enzyme coded for by SOD1 carries out a very important function in cells: it removes dangerous superoxide radicals by converting them into non-harmful substances. Defects in the action of this enzyme mean that the superoxide radicals attack cells from the inside, causing their death. Several different mutations in this enzyme all result in ALS, making the exact molecular cause of the disease difficult to ascertain.

Recent research has suggested that treatment with drugs called antioxidants may benefit ALS patients. However, since the molecular genetics of the disease are still unclear, a significant amount of research is still required to design other promising treatments for ALS.
Robert G. Miller awarded $1.5 million grant to help fund Neuraltus' Phase 2 clinical study of NP001 for ALS

Robert G. Miller awarded $1.5 million grant to help fund Neuraltus' Phase 2 clinical study of NP001 for ALS

Neuraltus Pharmaceuticals, Inc., a privately-held biopharmaceutical company focused on the development of groundbreaking drugs to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), announced today that Robert G. Miller, M.D., Director of the Forbes Norris MDA/ALS Research Center at Sutter Health's California Pacific Medical Center in San Francisco, has been awarded a grant from The ALS Association for $1.5 million to help fund a Phase 2 clinical study of the company's investigational therapy for ALS, NP001. [More]
ALS ACT initiative to speed discovery of new ALS treatments

ALS ACT initiative to speed discovery of new ALS treatments

The ALS Association and the ALS Finding a Cure Foundation are pleased to announce $3 million in funding for two new Phase II clinical studies through the ALS Accelerated Therapeutics (ALS ACT) initiative. [More]
Stanford researchers find how neurons work together to control movement in people with paralysis

Stanford researchers find how neurons work together to control movement in people with paralysis

Stanford University researchers studying how the brain controls movement in people with paralysis, related to their diagnosis of Lou Gehrig's disease, have found that groups of neurons work together, firing in complex rhythms to signal muscles about when and where to move. [More]
Immune system linked to death of motor neurons in Amyotrophic lateral sclerosis

Immune system linked to death of motor neurons in Amyotrophic lateral sclerosis

A previously unknown link between the immune system and the death of motor neurons in Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, has been discovered by scientists at the CHUM Research Centre and the University of Montreal. The finding paves the way to a whole new approach for finding a drug that can cure or at least slow the progression of such neurodegenerative diseases as ALS, Alzheimer's, Parkinson's and Huntington's diseases. [More]
Cytokinetics, The ALS Association expand partnership to fight against ALS

Cytokinetics, The ALS Association expand partnership to fight against ALS

Cytokinetics, Incorporated and The ALS Association announced an expanded partnership in which the company will provide Gold Level Sponsorship of the National Walks to Defeat ALS as well as Platinum Level Sponsorship for ALS Association Golden West Chapter initiatives. [More]
Researchers developing probe wire to better understand causes of degenerative brain diseases

Researchers developing probe wire to better understand causes of degenerative brain diseases

Researchers are developing a tiny wire that will speed up the discovery of new drugs and could one day unlock the mysteries of illnesses such as Alzheimer's or Lou Gehrig's disease. [More]
U of T researchers uncover new insights on genetic causes of ALS

U of T researchers uncover new insights on genetic causes of ALS

Researchers at the University of Toronto have uncovered new insights on the genetic causes of Amyotrophic Lateral Sclerosis (ALS), which is also known as Lou Gehrig's disease. These findings could uncover a new way to detect a genetic predisposition to ALS before the disease strikes. [More]
Mayo Clinic scientists create mouse model of ALS, FTD caused by mutations in C9ORF72 gene

Mayo Clinic scientists create mouse model of ALS, FTD caused by mutations in C9ORF72 gene

Scientists at Mayo Clinic, Jacksonville, Florida created a novel mouse that exhibits the symptoms and neurodegeneration associated with the most common genetic forms of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), both of which are caused by a mutation in the a gene called C9ORF72. [More]
Tuberous Sclerosis Alliance to observe fourth annual TSC Global Awareness Day

Tuberous Sclerosis Alliance to observe fourth annual TSC Global Awareness Day

On May 15, the Tuberous Sclerosis Alliance (TS Alliance) will join tuberous sclerosis complex (TSC) organizations around the world to observe the fourth annual TSC Global Awareness Day. [More]
Johns Hopkins researchers create the largest library of brain cells from ALS patients

Johns Hopkins researchers create the largest library of brain cells from ALS patients

Researchers at Johns Hopkins Medicine have transformed skin cells from patients with Lou Gehrig’s disease, or amyotrophic lateral sclerosis (ALS), into brain cells affected by the progressive, fatal disease and deposited those human-made cells into the first public ALS cell library, enabling scientists to better study the disease. [More]
Study reveals how cell's protein quality control mechanism helps combat neurodegenerative diseases

Study reveals how cell's protein quality control mechanism helps combat neurodegenerative diseases

A molecular pathway known to suppress tumors appears to also be a major player in clearing cells of damaged proteins implicated in neurodegenerative diseases such as ALS and certain types of dementia, new research in roundworms and human cells suggests. [More]
Study finds link between neurodegenerative disorders and inflammation

Study finds link between neurodegenerative disorders and inflammation

Researchers from McMaster University and the Icahn School of Medicine at Mount Sinai, New York have discovered that a protein associated with neurodegenerative diseases like ALS also plays an important role in the body's natural antiviral response. [More]
Discovery opens new drug development avenues for treating multiple diseases

Discovery opens new drug development avenues for treating multiple diseases

Researchers at the University of California, San Diego School of Medicine have discovered a control switch for the unfolded protein response (UPR), a cellular stress relief mechanism drawing major scientific interest because of its role in cancer, diabetes, inflammatory disorders and several neural degenerative disorders, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS), otherwise known as Lou Gehrig's disease. [More]
Neuralstem reports top line data from NSI-566 Phase II trial for treatment of ALS

Neuralstem reports top line data from NSI-566 Phase II trial for treatment of ALS

Neuralstem, Inc. announced top line data from the Phase II trial of NSI-566 spinal cord-derived neural stem cells under development for the treatment of amyotrophic lateral sclerosis (ALS). The study met primary safety endpoints. The maximum tolerated dose of 16 million transplanted cells and the surgery was well tolerated. [More]
Pollution effect: Potentially toxic microbes pose threat to drinking water

Pollution effect: Potentially toxic microbes pose threat to drinking water

Potentially toxic microbes which pose a threat to our drinking water have undergone a dramatic population explosion over the last 200 years as a result of pollution, research involving experts from The University of Nottingham has found. [More]

TSRI scientists find drug candidates that can prevent degeneration of brain cells in Parkinson's

In a pair of related studies, scientists from the Florida campus of The Scripps Research Institute have shown their drug candidates can target biological pathways involved in the destruction of brain cells in Parkinson's disease. [More]
Scientists identify new molecular pathway that controls axonal degeneration following injury

Scientists identify new molecular pathway that controls axonal degeneration following injury

Axons connect neurons with each other to form the neural networks that underpin the vital functions of perception, motility, cognition, and memory. In many neurodegenerative disorders, from traumatic injury or toxic damage to diseases such as Alzheimer's or Parkinson's disease, axonal degeneration represents an essential pathological feature. [More]
New discovery may help doctors develop better treatments for brain, spinal cord injuries

New discovery may help doctors develop better treatments for brain, spinal cord injuries

In a discovery that could dramatically affect the treatment of brain and spinal cord injuries, researchers have identified a previously unknown, beneficial immune response that occurs after injury to the central nervous system. [More]
Neurological testing accessibility and affordability: an interview with Dr Joseph Higgins

Neurological testing accessibility and affordability: an interview with Dr Joseph Higgins

Neurological disorders with genetic causes can be very difficult to diagnose without reliable, clinically relevant tests tailored to specific phenotypes. [More]
ALS Association announces research funds to further understand genetic cause of ALS

ALS Association announces research funds to further understand genetic cause of ALS

The ALS Association is pleased to announce the award of $326,662 in research funds to expand ongoing natural history studies in order to further understand the most common genetic cause of ALS, in preparation for clinical trials in those whose disease is affected by this gene. [More]
Advertisement
Advertisement